CONTRACEPTION BY AN INJECTABLE LONG-ACTING OESTROGEN-PROGESTOGEN AGENT. II.

Publisher Website
Google Scholar
Abstract
The results of a clinical investigation on 22 fertile women treated cyclically with a total of 341 injections of Deladroxate, an injectable, long-acting oestrogen-progestogen are presented. The injections were administered on the 8th (7th–9th) day of each cycle. Before treatment, the patients were observed through 2 cycles for cycle length as well as duration and amount of flow. In some cases the dose was increased because of a shortening of the cycle. The over all mean cycle length during the treatment was 25.3 days, though with fairly marked variations. The mean cycle length before treatment was 28.4 days. The duration of flow ranged from 1–30 days. About 72% of 320 withdrawal bleedings lasted for 4–8 days. Of the flows 60% were of normal amounts, while the majority of the remaining flows were scantier than the normal pre-treatment flows of the subjects. Side effects during treatment were recorded in one or more cycles in 17 of the 22 subjects and were in most cases slight and transient. The most common complaints were breast tenderness, oedema, and irregularities of bleeding. No pregnancy occurred during treatment. After discontinuation of the injections, bleedings and cycles normalized spontaneously in 11 women. In 1 woman curettage was performed because of profuse flow, and 2 women were treated with oral oestrogen-progestogens because of persistent bleeding. Eight women started oral contraception before the cycles became regular.

This publication has 0 references indexed in Scilit: